PRESCRIPTION DRUGS:
Medicare Overpaid $110 Million For Part B Drugs
Published on Sun Feb 26, 2006
IOG report could trigger a future slash in drug payments.
This may be hard to believe, but the HHS Office of Inspector General believes the Centers for Medicare & Medicaid Services is overpaying providers for many Part B drugs.
Inconsistent accounting practices have led CMS to overestimate many drug costs, the OIG says in "Calculation of Volume-Weighted Average Sales Price For Medicare Part B Prescription Drugs," OEI-03-05-00310.
Some 46 percent of drug codes had more reimbursement than they should have, which meant Medicare overpaid providers by $115 million in 2005. For another 13 percent of drug codes, Medicare underpaid, costing providers an estimated $5 million.
CMS should correct its method of calculating drug reimbursements, the OIG advises. The discrepancies in drug payments may only become more significant as CMS continues to adjust drug payments in response to OIG surveys.
CMS agreed with the OIG's findings and said it would consider adjusting the way it calculates drug payment levels. But CMS said it offered its current formula for public comment in the Federal Register, and the agency is still getting used to calculating drug payments based on Average Sales Price instead of Average Wholesale Price.
OIG Has Adverse Reaction To Substandard Care
Medicare paid $75 million for allergen immunotherapy and related services that didn't come up to proper standards, the OIG says in another report, "Allergen Immunotherapy For Medicare Beneficiaries," OEI-09-00-00531. Some 31 percent of allergy treatments in 2001 weren't medically necessary. Claims for an incorrect code accounted for another 7 percent, and billers failed to document another 29 percent of services.
Not only that, but some carriers have come up with local standards that don't follow national guidelines for allergy care, the OIG warns. One carrier allows providers to give injections at home, even though the national Joint Taskforce on Practice Parameters says patients should receive shots only in a clinic setting because of the risk of adverse reactions.
Roughly 70 percent of allergy patients in 2001 received care that didn't follow professionally recognized standards of care, the OIG adds. One in five patients didn't have a condition that required allergy shots. And another 13 percent had conditions that contraindicated the use of allergy shots.
Medicare payments for allergy shots increased from $130 million in 2001 to $171 million 2003. The OIG did a study of 1,434 allergen immunotherapy treatments physicians provided to 400 allergy patients in 2000, and found most patients received "substandard and poorly documented care." These findings led the OIG to look further at allergy claims in 2001.
The OIG urged CMS to come up with national coverage guidelines for allergen immunotherapy and similar treatments. Also, CMS should have the carriers educate physicians on allergy billing. CMS responded that issuing a new national coverage determination or adopting Joint [...]
